NORTH
CHICAGO, Ill. and SHANGHAI, Jan. 13,
2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere
Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX:
2096) today announced an option to license agreement to develop
SIM0500, an investigational new drug candidate. SIM0500 is
currently in Phase 1 clinical trials in patients with relapsed or
refractory multiple myeloma (MM), in both China and the U.S.
SIM0500 is a humanized trispecific antibody that targets GPRC5D,
BCMA, and CD3, developed independently by Simcere Zaiming using
their T-cell engager polyspecific antibody technology platform.
This molecule features a low affinity/high target-activating CD3
engaging arm and binding sites for the two tumor antigens:
G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell
maturation antigen (BCMA). SIM0500 has shown strong T cell
cytotoxicity against multiple myeloma (MM) cells by leveraging a
combination of various antitumor effects.
"As a leader in hematologic malignancies, AbbVie is committed to
advancing innovative treatments for complex cancers like multiple
myeloma through our relentless R&D efforts and collaborations,"
said Mariana Cota Stirner, M.D.,
Ph.D., vice president, therapeutic area head for hematology,
AbbVie. "We look forward to partnering with Simcere Zaiming, to
advance this novel trispecific antibody, which has the potential to
help address significant unmet medical needs for people living with
multiple myeloma"
"SIM0500 is developed via Simcere Zaiming's proprietary
T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere
Zaiming. "We are excited to partner with AbbVie on this novel drug
candidate and look forward to working together to advance the
clinical development of SIM0500. "
Simcere Zaiming will receive an upfront payment from AbbVie and
is eligible to receive option fees and milestone payments of up to
$1.055B, as well as tiered royalties
on net sales outside of the Greater
China territory. AbbVie is eligible to receive tiered
royalties on net sales in the Greater
China territory.
About AbbVie in Oncology
At AbbVie, we are committed
to transforming standards of care for patients living with
difficult-to-treat cancers. We are advancing a dynamic pipeline of
investigational therapies across a range of cancer types in both
blood cancers and solid tumors. We are focusing on creating
targeted medicines that either impede the reproduction of cancer
cells or enable their elimination. We achieve this through various,
targeted treatment modalities and biology interventions, including
small molecule therapeutics, antibody-drug conjugates (ADCs),
immuno-oncology-based therapeutics, multispecific antibody and in
situ CAR-T platforms. Our dedicated and experienced team joins
forces with innovative partners to accelerate the delivery of
potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and
investigational treatments for a wide range of blood and solid
tumors. We are evaluating more than 20 investigational medicines in
multiple clinical trials across some of the world's most widespread
and debilitating cancers. As we work to have a remarkable impact on
people's lives, we are committed to exploring solutions to help
patients obtain access to our cancer medicines. For more
information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines and solutions that solve serious
health issues today and address the medical challenges of tomorrow.
AbbVie strives to have a remarkable impact on people's lives across
several key therapeutic areas – immunology, oncology, neuroscience,
and eye care – and products and services in AbbVie's Allergan
Aesthetics portfolio. For more information about AbbVie, please
visit us at www.abbvie.com. Follow @abbvie
on LinkedIn, Facebook, Instagram, X (formerly
Twitter), and YouTube.
About Simcere Zaiming
Simcere Zaiming is an
oncology-focused biopharmaceutical company and a subsidiary of
Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere").
Founded in 2023, Simcere Zaiming dedicated to developing
groundbreaking therapies to meet the unmet clinical needs of cancer
patients globally. With a robust and innovative R&D pipeline
featuring distinct clinical assets, Simcere Zaiming has
successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®,
and Enlituo®. The company is determined to deliver potentially
transformative treatment options to cancer patients worldwide
through its internal R&D, manufacturing, and commercialization
capabilities, complemented by strategic collaborations with leading
partners.
View original
content:https://www.prnewswire.com/news-releases/abbvie-and-simcere-zaiming-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-in-multiple-myeloma-302348650.html
SOURCE AbbVie
